Johnson & Johnson Family of Companies
1 Johnson & Johnson Plaza
New Brunswick
New Jersey
08933
United States
Tel: 732-524-0400
Fax: 732-524-3300
Website: http://www.jnj.com/
2205 articles with Johnson & Johnson Family of Companies
-
Johnson & Johnson Reports 2019 Third-Quarter Results
10/15/2019
Johnson & Johnson announced results for third-quarter 2019.
-
Employees’ Perception vs. Employers’ Reality! New Research Shows the Top 3 Areas of Opportunity
10/14/2019
What makes an organization a desirable employer? Do they need to be a large company with a recognizable name? Should the organization pay their employees more than others? -
GlobalData recently published their top 20 global pharma companies categorized by market capitalization in the first quarter of 2019.
-
The jury found the company failed to warn patients of a side effect causing young men who used the drug to grow breasts (gynecomastia).
-
McKool Smith Secures Federal Circuit Win in Surgical Device Suit Against Acclarent
10/8/2019
On October 4, 2019, the U.S. Court of Appeals for the Federal Circuit affirmed McKool Smith's inter partes review (IPR) trial victory on behalf of patent owner Dr. Ford Albritton IV against medical device maker Acclarent, a Johnson & Johnson subsidiary.
-
Johnson & Johnson Commits $500 Million Investment Over Four Years to Help End the Epidemics of HIV and Tuberculosis
10/4/2019
Johnson & Johnson announced it has committed to ensuring more than $500 million is dedicated to world class research & development and delivery programs over the next four years to accelerate global efforts to eliminate HIV and tuberculosis by 2030.
-
Janssen Submits Supplemental New Drug Application to U.S. FDA for SPRAVATO® (esketamine) CIII Nasal Spray for the Rapid Reduction of Depressive Symptoms in Adults with Major Depressive Disorder Who Have Active Suicidal Ideation with Intent
10/2/2019
If approved, SPRAVATO® would be the first treatment for this severely ill population(1) who historically have been excluded from antidepressant clinical trials
-
Johnson & Johnson reached a $20 million settlement agreement with two Ohio counties for its role in the opioid crisis ahead of a watershed trial set to take place later this month involving multiple companies and lawsuits.
-
FDA Approves New Drug to Treat Diabetes-Related Kidney Disease
9/30/2019
The National Kidney Foundation Statement about INVOKANA® (Canagliflozin)
-
California Jury Returns $40 Million Talc Verdict Against Johnson & Johnson
9/30/2019
Simon Greenstone Panatier prevails in its second talc case against JNJ in a month
-
According to the second biennial 2019 Life Sciences Ideal Employer Report by BioSpace, the top three most important attributes cited by life sciences professionals around the world are the opportunity to do interesting and meaningful work, a competitive salary and health benefits.
-
BioSpace, the leader in life sciences news and careers, today announced that Genentech, Pfizer, Merck, Amgen and Novartis landed in the top five spots of their latest Ideal Employer report.
-
Ethicon Launches Industry's First Powered Circular Stapler For Colorectal, Gastric And Thoracic Surgery
9/24/2019
New ECHELON CIRCULAR™ Powered Stapler Results in 61% Fewer Leaks at the Staple Line¹
-
Artist/Activist Domenic Esposito Places 800 lb Opioid Spoon Sculpture at Johnson & Johnson Headquarters to Shine a Light on Sinister Opioid Production and Distribution Practices
9/18/2019
With the recent verdict against Johnson & Johnson, whereby Judge Thad Balkman ordered the company to pay Oklahoma $572 Million, ruling that J& J is responsible for fueling Oklahoma's opioid crisis, this art-activism was designed to inform the public that J&J has played a much larger role in the nation's on-going opioid epidemic.
-
Johnson & Johnson to Host Investor Conference Call on 2019 Third Quarter Results
9/18/2019
Johnson & Johnson will host a conference call for investors at 8:30 a.m. on Tuesday, October 15th to review third-quarter results.
-
Erleada is an androgen receptor inhibitor approved for non-metastatic castration-resistant prostate cancer.
-
Improving Patient Outcomes Overtakes Reducing Costs as Top Priority for U.S. Health System Leaders
9/16/2019
Survey Explores Perspectives of Health System Executives and Clinicians Across the U.S.
-
New DARZALEX® (daratumumab) Data from GRIFFIN Study Show High Response Rate and Depth of Response in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant-Eligible
9/15/2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the randomized Phase 2 GRIFFIN (MMY2004) study showing that the addition of DARZALEX® (daratumumab) to bortezomib, lenalidomide and dexamethasone (VRd) induced higher response rates in newly diagnosed patients with multiple myeloma who were eligible for high-dose therapy and autologous stem cell transplantation (ASCT) compared with VRd alone.
-
DePuy Synthes Expands ATTUNE Knee Platform with Cementless Option
9/9/2019
Cementless technology supports growing trend of younger, more active patients undergoing knee replacement [09-September-2019] WARSAW, Ind. , Sept. 9, 2019 /PRNewswire/ -- Johnson & Johnson Medical Devices Companies* announced today that DePuy Synthes** is launching the ATTUNE Cementless Knee in a rotating platform option in select markets around the world. This la
-
European Commission Approves Expanded Use of Janssen’s STELARA® (ustekinumab) for the Treatment of Moderately to Severely Active Ulcerative Colitis in the European Union
9/4/2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission has approved the expanded use of ustekinumab for the treatment of adults with moderately to severely active ulcerative colitis, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.